Physician profile
Hal S Pineless
NPI 1114917978
$23,577.64
in general payments reported to CMS, 2019-2025
65 companies · $2,012 in 2025
The $2,012 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,736 · 2020: $5,114 · 2021: $8,703 · 2022: $1,520 · 2023: $1,768 · 2024: $1,724 · 2025: $2,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,486 · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,486.46 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,043.44 | 2021-2025 | |
| Allergan, INC. | $5,673.95 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $929.52 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lilly USA, LLC | $872.76 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Ucb, INC. | $852.00 | 2019-2025 | Briviact, Rystiggo, Zilbrysq |
| Genentech USA, INC. | $795.56 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Pfizer INC. | $665.30 | 2021-2025 | |
| Biogen, INC. | $563.25 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Abbott Laboratories | $493.41 | 2019-2023 | Infinity |
| Eisai INC. | $490.89 | 2019-2025 | |
| Argenx US, INC. | $475.13 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $423.07 | 2019-2025 | Rytary, Crexont, Ongentys |
| Sunovion Pharmaceuticals INC. | $361.60 | 2019-2021 | |
| Genzyme Corporation | $298.85 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $263.95 | 2019-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Pineless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.